Dieter A Häring Selected Research

ofatumumab

10/2022	Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
1/2022	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
1/2022	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
1/2022	Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
1/2022	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
1/2022	Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.
12/2020	Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
1/2020	Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dieter A Häring Research Topics

Disease

20	Multiple Sclerosis 10/2022 - 01/2016
9	Relapsing-Remitting Multiple Sclerosis 01/2022 - 08/2013
2	Disease Progression 01/2022 - 03/2016
2	Chronic Progressive Multiple Sclerosis 01/2022 - 03/2016
2	Atrophy 01/2022 - 01/2020
1	Body Weight (Weight, Body) 01/2022
1	Acute Disease 01/2022
1	Psoriatic Arthritis 11/2021
1	Rheumatoid Arthritis 11/2021
1	Axial Spondyloarthritis 11/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2021
1	Atrioventricular Block 03/2016
1	Bradycardia 03/2016
1	Basal Cell Carcinoma (Rodent Ulcer) 03/2016
1	Lymphopenia (Lymphocytopenia) 03/2016
1	Inflammation (Inflammations) 01/2016

Drug/Important Bio-Agent (IBA)

13	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022 - 08/2013
8	ofatumumab FDA Link 10/2022 - 01/2020
4	Monoclonal AntibodiesIBA 10/2022 - 01/2022
4	GadoliniumIBA 01/2022 - 01/2016
4	InterferonsIBA 01/2022 - 12/2019
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2019
2	Natalizumab (Tysabri)FDA Link 01/2022 - 01/2022
2	teriflunomideIBA 01/2022 - 01/2020
1	ocrelizumabIBA 10/2022
1	siponimodIBA 01/2022
1	EpitopesIBA 01/2022
1	secukinumabIBA 11/2021
1	Sphingosine-1-Phosphate ReceptorsIBA 03/2016
1	Interferon-betaIBA 08/2013

Therapy/Procedure

6	Therapeutics 10/2022 - 01/2016
1	Injections 01/2020